Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dyne Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.dyne-tx.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: John G. Cox, MBA
Number Of Employees: 191
Enterprise Value: $1,599,742,391
PE Ratio: -3.52
Exchange/Ticker 1: NASDAQ:DYN
Exchange/Ticker 2: N/A
Latest Market Cap: $1,334,827,776
BioCentury | Mar 21, 2025
Management Tracks
Dyne names Editas’ Erick Lucera CFO
Plus: Amy Parison to succeed Lucera at Editas, and a new CEO at Akari
BioCentury | Jan 22, 2025
Product Development
Vir, Sana gain new modality POC: BioCentury’s Clinical Report
Plus readouts from Jasper, Dyne and more
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Jan 13, 2025
Guest Commentary
Navigating biotech investment cycles — the true north: Guest Commentary
Biotech VC Uciane Scarlett on getting the right mix of platform-to-asset
BioCentury | Nov 26, 2024
Management Tracks
Susanna High named CEO of Paragon
Plus: Lee Patterson becomes CEO of Metrion, and updates from Rondo, AffyImmune and Aspargo
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Oct 15, 2024
Finance
Forbion’s European capital wave
Sticking to its strategy, firm raises $2.2B just 18 months after raising $1.5B
BioCentury | Sep 25, 2024
Product Development
Wave claims early lead in second-generation exon 53 skipping
In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more
BioCentury | Sep 19, 2024
Management Tracks
EMA names Sepodes CHMP chair, Bell leaving Valo as CEO, and more
Plus: Autolus hires Matthias Will as CDO, and updates from HotSpot, Prilenia, Frazier, BIA and BioCentriq
BioCentury | Sep 4, 2024
Management Tracks
Evers leaving Evotec as CBO
Plus: C-suite changes at Dyne, and updates from Novocure, Amphista, reMYND, Belite Bio, Forward and more
Items per page:
1 - 10 of 47